CD95 apoptosis resistance in certain cells can be overcome by noncanonical activation of caspase-8

被引:10
作者
Barnhart, BC
Pietras, EM
Algeciras-Schimnich, A
Salmena, L
Sayama, K
Hakem, R
Peter, ME
机构
[1] Univ Chicago, Ben May Inst Canc Res, Chicago, IL 60637 USA
[2] Univ Shizuoka, Shizuoka, Japan
[3] Univ Toronto, Ontario Canc Inst, Adv Med Discovery Inst, Dept Med Biophys, Toronto, ON, Canada
关键词
caspase-8; apoptosis; death domain; tumor cells; CD95; NF-kappaB;
D O I
10.1038/sj.cdd.4401509
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
CD95 apoptosis resistance of tumor cells is often acquired through mutations in the death domain (DD) of one of the CD95 alleles. Furthermore, Type I cancer cells are resistant to induction of apoptosis by soluble CD95 ligand (CD95L), which does not induce efficient formation of the death-inducing signaling complex (DISC). Here, we report that tumor cells expressing a CD95 allele that lacks a functional DD, splenocytes from heterozygous Ipr(cg) mice, which express one mutated CD95 allele, and Type I tumor cells stimulated with soluble CD95L can all die through CD95 when protein synthesis or nuclear factor kappa B is inhibited. This noncanonical form of CD95-mediated apoptosis is dependent on the enzymatic activity of procaspase-8 but does not involve fully processed active caspase-8 subunits. Our data suggest that it is possible to overcome the CD95 apoptosis resistance of many tumor cells that do not efficiently form a DISC through noncanonical activation of the caspase-8 proenzyme.
引用
收藏
页码:25 / 37
页数:13
相关论文
共 41 条
[31]   Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity [J].
Schneider, P ;
Holler, N ;
Bodmer, JL ;
Hahne, M ;
Frei, K ;
Fontana, A ;
Tschopp, J .
JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 187 (08) :1205-1213
[32]   Fas preassociation required for apoptosis signaling and dominant inhibition by pathogenic mutations [J].
Siegel, RM ;
Frederiksen, JK ;
Zacharias, DA ;
Chan, FKM ;
Johnson, M ;
Lynch, D ;
Tsien, RY ;
Lenardo, MJ .
SCIENCE, 2000, 288 (5475) :2354-2357
[33]   Inactivation of caspase-8 on mitochondria of Bcl-xL-expressing MCF7-Fas cells -: Role for the bifunctional apoptosis regulator protein [J].
Stegh, AH ;
Barnhart, BC ;
Volkland, J ;
Algeciras-Schimnich, A ;
Ke, N ;
Reed, JC ;
Peter, ME .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (06) :4351-4360
[34]   EXPRESSION OF THE FUNCTIONAL SOLUBLE FORM OF HUMAN FAS LIGAND IN ACTIVATED LYMPHOCYTES [J].
TANAKA, M ;
SUDA, T ;
TAKAHASHI, T ;
NAGATA, S .
EMBO JOURNAL, 1995, 14 (06) :1129-1135
[35]   Downregulation of Fas ligand by shedding [J].
Tanaka, M ;
Itai, T ;
Adachi, M ;
Nagata, S .
NATURE MEDICINE, 1998, 4 (01) :31-36
[36]   Caspase- and serine protease-dependent apoptosis by the death domain of FADD in normal epithelial cells [J].
Thorburn, J ;
Bender, LM ;
Morgan, MJ ;
Thorburn, A .
MOLECULAR BIOLOGY OF THE CELL, 2003, 14 (01) :67-77
[37]   MONOCLONAL-ANTIBODY - MEDIATED TUMOR-REGRESSION BY INDUCTION OF APOPTOSIS [J].
TRAUTH, BC ;
KLAS, C ;
PETERS, AMJ ;
MATZKU, S ;
MOLLER, P ;
FALK, W ;
DEBATIN, KM ;
KRAMMER, PH .
SCIENCE, 1989, 245 (4915) :301-305
[38]   Dual signaling of the Fas receptor: Initiation of both apoptotic and necrotic cell death pathways [J].
Vercammen, D ;
Brouckaert, G ;
Denecker, G ;
Van de Craen, M ;
Declercq, W ;
Fiers, W ;
Vandenabeele, P .
JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 188 (05) :919-930
[39]   TRAIL-R2: A novel apoptosis-mediating receptor for TRAIL [J].
Walczak, H ;
DegliEsposti, MA ;
Johnson, RS ;
Smolak, PJ ;
Waugh, JY ;
Boiani, N ;
Timour, MS ;
Gerhart, MJ ;
Schooley, KA ;
Smith, CA ;
Goodwin, RG ;
Rauch, CT .
EMBO JOURNAL, 1997, 16 (17) :5386-5397
[40]   Immunological characterization of C3H mice congenic for Faslprcg, C3H/HeJ-Faslprcg/Faslprcg [J].
Yasuda, T ;
Zhang, Y ;
Nagase, H ;
Kaneko, T ;
Sayama, K ;
Hashimoto, H ;
Matsuzawa, A .
LABORATORY ANIMALS, 2000, 34 (01) :46-55